| Title: | Interplay between microRNAs, serum proprotein convertase subtilisin/kexin type 9 (PCSK9), and lipid parameters in patients with very high lipoprotein(a) treated with PCSK9 inhibitors |
|---|
| Authors: | ID Levstek, Tina (Author)
ID Karun, Tina (Author)
ID Rehberger Likozar, Andreja (Author)
ID Šebeštjen, Miran (Author)
ID Trebušak Podkrajšek, Katarina (Author) |
|---|
| Files: |  PDF - Presentation file, download (2,23 MB)
MD5: 0BDFB3185B9E7492ED7798735E2C4621
 URL - Source URL, visit https://www.mdpi.com/2073-4425/14/3/632
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Proprotein convertase subtilisin/kexin type 9 (PCSK9) has an important function in the regulation of lipid metabolism. PCSK9 reduces hepatic low-density lipoprotein receptors, thereby increasing low-density lipoprotein cholesterol levels. However, its regulation remains to be elucidated, including post-transcriptional regulation by microRNAs (miRNAs). We aimed to explore the interplay between miRNAs, total serum PCSK9, and lipids during treatment with PCSK9 inhibitors. A total of 64 patients with stable coronary artery disease and very high lipoprotein(a) levels and 16 sex- and age-matched control subjects were enrolled. Patients received a PCSK9 inhibitor (evolocumab or alirocumab). Total serum PCSK9 levels were measured by immunoassay. RNA was isolated from plasma using magnetic beads, and expression of selected miRNAs was analyzed by quantitative PCR. Total serum PCSK9 levels were significantly higher in control subjects compared with patients. After 6 months of treatment with PCSK9 inhibitors, total serum PCSK9 levels increased significantly. The expression of miR-191-5p was significantly lower, and the expression of miR-224-5p and miR-483-5p was significantly higher in patients compared with control subjects. Using linear regression, the expression of miR-483-5p significantly predicted the serum PCSK9 level at baseline. After the 6-month period of therapy, the expression of miR-191-5p and miR-483-5p significantly increased. Our results support a role for miR-483-5p in regulating circulating PCSK9 in vivo. The difference in expression of miR-191-5p, miR-224-5p, and miR-337-3p between patients and control subjects suggests their possible role in the pathogenesis of coronary artery disease. |
|---|
| Keywords: | cardiovascular disease, PCSK9, microRNA, lipoprotein(a), PCSK9 inhibitors, lipid parameters, biomarker |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2023 |
|---|
| Number of pages: | 1-13 str. |
|---|
| Numbering: | Vol. 14, iss. 3, [article no.] 632 |
|---|
| PID: | 20.500.12556/DiRROS-32343  |
|---|
| UDC: | 616.1 |
|---|
| ISSN on article: | 2073-4425 |
|---|
| DOI: | 10.3390/genes14030632 |
|---|
| COBISS.SI-ID: | 144230147 |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 7. 3. 2023;
|
|---|
| Pub. date in DiRROS: | 07.09.2026 |
|---|
| Views: | 36 |
|---|
| Downloads: | 15 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
